1	Multi-analyte proteomic analysis identifies blood-based neuroinflammation,
2	cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease
3	Xuemei Zeng ¹ · Tara K. Lafferty ¹ · Anuradha Sehrawat ¹ · Yijun Chen ² · Pamela C. L. Ferreira ¹ ·
4	Bruna Bellaver ¹ \cdot Guilherme Povala ¹ \cdot M. Ilyas Kamboh ³ \cdot William E. Klunk ¹ \cdot Ann D. Cohen ¹ \cdot
5	Oscar L. Lopez ⁴ · Milos D. Ikonomovic ^{1,4,5} · Tharick A. Pascoal ¹ · Mary Ganguli ^{1,4,6} · Victor L.
6	Villemagne ¹ · Beth E. Snitz ⁴ · Thomas K. Karikari ¹ *
7	
8	¹ Department of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street,
9	Pittsburgh, PA 15213, USA
10	² Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15213, USA
11	³ Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh,
12	PA 15213, USA
13	⁴ Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213,
14	USA
15	⁵ Geriatric Research Education and Clinical Center, VA Pittsburgh HS, Pittsburgh, PA, USA
16	⁶ Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh,
17	Pennsylvania, USA
18	

- 19 *Corresponding author. Department of Psychiatry, School of Medicine, University of Pittsburgh,
- 20 Pittsburgh 15213, PA, USA. Email: Karikaritk@upmc.edu

21 Abstract

Background: Blood-based biomarkers are gaining grounds for Alzheimer's disease (AD) detection. However, two key obstacles need to be addressed: the lack of methods for multianalyte assessments and the need for markers of neuroinflammation, vascular, and synaptic dysfunction. Here, we evaluated a novel multi-analyte biomarker platform, NULISAseq CNS disease panel, a multiplex NUcleic acid-linked Immuno-Sandwich Assay (NULISA) targeting ~120 analytes, including classical AD biomarkers and key proteins defining various disease hallmarks.

29 Methods: The NULISAseq panel was applied to 176 plasma samples from the MYHAT-NI 30 cohort of cognitively normal participants from an economically underserved region in Western Pennsylvania. Classical AD biomarkers, including p-tau181, p-tau217, p-tau231, GFAP, NEFL, 31 32 A640, and A642, were also measured using Single Molecule Array (Simoa). Amyloid pathology, 33 tau pathology, and neurodegeneration were evaluated with [11C] PiB PET, [18F]AV-1451 PET, and MRI, respectively. Linear mixed models were used to examine cross-sectional and 34 35 Wilcoxon rank sum tests for longitudinal associations between NULISA biomarkers and AD pathologies. Spearman correlations were used to compare NULISA and Simoa. 36

Results: NULISA concurrently measured 116 plasma biomarkers with good technical 37 38 performance, and good correlation with Simoa measures. Cross-sectionally, p-tau217 was the 39 top hit to identify Aβ pathology, with age, sex, and APOE genotype-adjusted AUC of 0.930 40 (95%CI: 0.878-0.983). Fourteen markers were significantly decreased in A β -PET+ participants, 41 including TIMP3, which regulates brain A β production, the neurotrophic factor BDNF, the energy 42 metabolism marker MDH1, and several cytokines. Longitudinally, FGF2, IL4, and IL9 exhibited Aβ PET-dependent yearly increases in Aβ-PET+ participants. Markers with tau PET-dependent 43 44 longitudinal changes included the microglial activation marker CHIT1, the reactive astrogliosis marker CHI3L1, the synaptic protein NPTX1, and the cerebrovascular markers PGF, PDGFRB, 45

and VEFGA; all previously linked to AD but only reliably measured in cerebrospinal fluid. SQSTM1, the autophagosome cargo protein, exhibited a significant association with neurodegeneration status after adjusting age, sex, and $APOE \varepsilon 4$ genotype.

49 **Conclusions:** Together, our results demonstrate the feasibility and potential of immunoassay-50 based multiplexing to provide a comprehensive view of AD-associated proteomic changes. 51 Further validation of the identified inflammation, synaptic, and vascular markers will be 52 important for establishing disease state markers in asymptomatic AD.

53 Keywords

54 Preclinical Alzheimer's disease; plasma biomarkers; proteomics; amyloid pathology; tau

55 pathology; neurodegeneration; NUcleic acid-Linked Immuno-Sandwich Assay (NULISA);

56 NULISA with next-generation sequencing readout (NULISAseq).

57

58 Background

59 The draft revision of the amyloid/tau/neurodegeneration (AT(N)) research framework 60 emphasizes the multifaceted nature of Alzheimer's disease (AD), involving diverse brain 61 pathologies and physiological processes [1]. In addition to A (β -amyloid deposition), T 62 (pathologic tau), and N (neurodegeneration) categories, which were included in the 2018 update 63 [2], the proposed upcoming revision recommends biomarker assessments for inflammation (I) 64 as well as mixed pathologies such as vascular (V) pathology and synucleinopathy (S). 65 Furthermore, alteration of synapses can occur early in the AD continuum, even before overt 66 neurodegeneration, making the examination of synaptic markers important in preclinical AD [3-67 5]. This new framework necessitates a diverse set of biomarkers for more accurate diagnosis, 68 prognosis, clinical management, and development/evaluation of therapies. Analyses of multiple 69 biomarkers integrated into a single test can enhance efficiency, reduce analytical errors, and

save on specimen volume. However, multi-analyte assays that provide concurrent information on A, T, and N processes are lacking, let alone those that concomitantly include I, V, and S biomarkers. In fact, glial fibrillary acidic protein (GFAP) is the only marker listed under I, while V has no entry in terms of biofluid biomarkers recommended in the draft revision of the research and diagnostic framework [1].

75 Previous analyses of cerebrospinal fluid (CSF) implicated associations of several inflammatory, 76 vascular, and synaptic function proteins with amyloid-beta (A β) and tau pathologies in AD. 77 Regarding neuroinflammation, the astrocytic protein chitinase-3 like-protein-1 (CHI3L1), also 78 known as YKL-40, has been shown to associate preferentially with tau pathology, while GFAP, a 79 different astrocytic protein, was more involved with Aß plaque pathology [6-9]. CSF levels of 80 soluble TREM2, a transmembrane receptor protein predominantly expressed by microglia cells, 81 were increased in AD and associated with tau-dependent neurodegeneration and cognitive 82 decline [10-13]. Levels of TREM1, another microglial transmembrane protein, were also shown 83 to increase in AD dementia compared with cognitively unimpaired controls and those with mild 84 cognitive impairment (MCI) [14]. In addition, multiple interleukins (ILs) in CSF were associated with Aβ and tau pathology, as well as cognitive decline [15-20]. Similarly, several CSF markers 85 86 of cerebrovascular integrity, such as sPDGFRB (soluble platelet-derived growth factor receptor 87 β), ICAM1, VCAM1, and VEGFs, synaptic markers such as NPTX and NRGN, have been linked 88 to AD and cognitive decline [18, 21-28]. High α -synuclein seed amplification assay positivity has 89 been found in AD and is associated with atypical clinical manifestation [29].

A major challenge in the AD biomarker field is the difficulty in accurately measuring the aforementioned neuroinflammation, cerebrovascular, and synaptic protein markers in blood samples to give reliable performances as shown for their CSF counterparts. The development of blood-based assays for these biomarkers has been greatly impeded by several factors, including interference from the extremely complex blood proteome, low abundance of the target

analytes, and signal attenuation by unwanted signal from peripheral sources [30, 31]. For
example, assays for synaptic markers including NRGN give good analytical signals in plasma
but without the corresponding good biomarker performance as shown in CSF [32, 33].

98 Recently, a highly multiplexed immunoassay capable of measuring classical AT(N) biomarkers 99 alongside multiple I, V, and S biomarkers in plasma has been described [34]. Known as the 100 NULISAseq CNS disease panel, this assay employs an innovative automated technology called 101 NUcleic acid-Linked Immuno-Sandwich Assay (NULISA). Coupling NULISA with next-generation 102 sequencing readout (NULISAseq) allows detection of hundreds of proteins with attomolar 103 sensitivity and an ultra-broad dynamic range [34]. The NULISAseg CNS panel consists of ~120 protein targets covering the eight pathological hallmarks that define neurodegenerative 104 105 diseases: namely, pathological protein aggregation, synaptic and neuronal network dysfunction, 106 aberrant proteostasis, cytoskeletal abnormalities, altered energy homeostasis, DNA and RNA 107 defects, inflammation, and neuronal cell death [35].

108 This study had a three-fold aim. Our first aim was to evaluate the technical performance of the 109 NULISAseq CNS disease panel. For classical AT(N) biomarkers (e.g., p-tau181, p-tau217, p-110 tau231, Aβ40, Aβ42, GFAP, and neurofilament light chain [NEFL]), we compared the NULISA 111 results with those obtained, in mostly single-plex formats, on the widely used Quanterix Single 112 molecule array (Simoa) platform. The second aim was to examine the diagnostic accuracies 113 and longitudinal profiles of blood-based NULISAseq targets against neuroimaging measures of A, T and N in a population-based cohort of mostly cognitively normal older adults. Thirdly, we 114 115 aimed to identify novel plasma I, V, and synaptic markers associated with Aß positron emission tomography (PET), tau PET and magnetic resonance imaging (MRI)-based neurodegeneration 116 117 measures in the same cohort.

118 Methods

119 Participants

The Monongahela Youghiogheny Healthy Aging Team-Neuroimaging (MYHAT-NI) is a sub-120 121 cohort of the parent MYHAT study, a population-based prospective study of cognitively normal 122 older adults designed to characterize the prevalence of MCI in older adults with a low socioeconomic status in selected Rust Belt regions in southwestern Pennsylvania [36-38]. The 123 124 MYHAT study recruited participants aged 65 and older via age-stratified random sampling from publicly available voter registration lists. The MYHAT-NI study recruited a subset of MYHAT 125 participants with a Clinical Dementia Rating (CDR) sum-of-box score [39] of < 1.0 for 126 127 neuroimaging assessments to investigate the distribution and functional correlates of AD 128 pathologies. For this reason, all MYHAT-NI participants had normal or only very mildly impaired 129 cognition at the time of enrollment which started in 2017. The only exclusion criterion was a 130 contraindication to neuroimaging. The study had two visits: baseline and approximately two-year 131 follow-up. Sociodemographic information was collected at the baseline visit. Blood collection, neurophysiological assessment, and neuroimaging, including [¹¹C] Pittsburgh Compound B 132 (PiB) positron emission tomography (PET) imaging of Aß plagues, [¹⁸F]AV-1451 PET imaging of 133 tau pathology, and structural MRI for neurodegeneration, were performed at both baseline and 134 135 the follow-up visits. Detailed study designs for MYHAT and MYHAT-NI, including subject 136 recruitment strategies, multi-domain cognitive assessments, neuroimaging, and data 137 processing, can be found in previous publications [36, 38]. APOE genotyping was determined as previously described [40]. 138

139

We classified participants' A, T, and N status according to [¹¹C] PiB PET, [¹⁸F]AV-1451 PET, and MRI scans for cortical thickness, respectively. The A status was based on a global [¹¹C] PiB standardized uptake value ratio (SUVR) computed by volume-weighted averaging of nine composite regional outcomes (anterior cingulate, posterior cingulate, insula, superior frontal

144 cortex, orbitofrontal cortex, lateral temporal cortex, parietal, precuneus, and ventral striatum) 145 [41]. Participants were classified as A+ or A- based on a pre-defined cutoff, with >1.346 as A+ [42, 43]. For T status, a composite SUVR was computed for each [¹⁸F]AV-1451 PET by 146 147 normalizing composite Braak regional values ((Braak I - VI) to FreeSurfer cerebellar gray matter 148 activity [44, 45]. Participants with SUVR > 1.18 were considered T+, <=1.18 as T- [46]. N status 149 was based on an AD-signature composite cortical thickness index derived from a surface-area 150 weighted average of the mean cortical thickness of four FreeSurfer regions of interest (ROIs) -151 entorhinal, inferior temporal, middle temporal, and fusiform - that are most predictive of AD-152 specific diagnosis and pathology, with < 2.7 as N+ [42, 47]. The MYHAT-NI study was approved by the University of Pittsburgh Institutional Review Board (STUDY19020264). 153

154

155 NULISAseq assay procedures and data processing

Plasma samples were thawed and centrifuged at 10,000xg for 10 min to remove particulates. 156 157 The supernatants were then analyzed using the NULISAseg CNS disease panel, an innovative proprietary proteomic platform, on an Alamar ARGO[™] prototype system, as previously 158 159 described [34]. In brief, samples were incubated with a cocktail of paired capture and detection 160 antibodies for the included target protein biomarkers and the internal control (IC). The capture 161 antibodies were conjugated with partially double-stranded DNA containing a poly-A tail and a 162 target-specific barcode, while detection antibodies were conjugated with another partially 163 double-stranded DNA containing a biotin group and a matching target-specific barcode. After 164 incubation, the mixtures underwent magnetic bead-based capture, wash, release, recapture, 165 and second round of wash processes to purify the formed immunocomplexes. A ligation mix. 166 including T4 DNA ligase and a specific DNA ligator sequence, was utilized to ligate the proximal 167 ends of DNA attached to the paired antibodies, generating DNA reporter molecules containing 168 unique target and sample-specific barcodes. The reporter DNA levels were then quantified by Next-Generation Sequencing (NGS). The plasma samples were randomized in two plates for 169

the assay. Three assay controls were run side-by-side with samples for each plate, including the
sample control (2 replicates/plate), the inter-plate control (3 replicates/plate), and the negative
control (2-3 replicates/plate).

173

174 Data normalization was performed to remove potential unwanted technical variation. First, IC-175 based normalization was done by dividing the target counts for each sample well by that well's 176 IC counts. IPC normalization was achieved by dividing IC-normalized counts by target-specific 177 medians of the IPC (pooled plasma) sample replicates on that plate. Finally, the data was 178 rescaled and log2-transformed to give a more normal distribution for subsequent statistical 179 analyses. These values are hereafter referred to as NULISA Protein Quantification (NPQ) units. The fold change difference between two groups were calculated as 2^(difference in NPQ). The plate-180 181 specific limit of detection (LOD) was calculated for each target assay by taking the mean plus 182 three times the standard deviation of the unlogged normalized counts for the negative control 183 samples on the plate. LODs were then rescaled and log2-transformed as above.

184

185 Procedures for Simoa assays

186 Simoa assays were performed on an HD-X instrument (Quanterix, Billerica, MA, USA). Prior to 187 the measurements, plasma samples were thawed at room temperature and centrifuged at 188 4000xg for 10 min to remove particulates. Plasma NEFL, GFAP, AB42 and AB40 were measured 189 with the Neurology 4-Plex E (#103670), p-tau181 with the p-tau181 V2 Advantage kit (#103714), 190 and p-tau217 with the ALZpath Simoa® p-Tau 217 V2 Assay Kit (#104371). Quality control (QC) 191 samples of 2-3 different concentrations for each assay were analyzed at the start and the end of 192 each run to assess the reproducibility of each assay. The average within-run coefficient of 193 variations (CVs) of the QC samples were 3.7% for p-tau217, 6.6% for p-tau181, 14.3 for NEFL, 194 9.9% for GFAP, 8.9% for Aβ42, and 9.5% for Aβ40. The average between-run CVs were 11.4%

for p-tau217, 11.7% for p-tau181, 18.3% for NEFL, 17.8% for GFAP, 13.0% for Aβ42, and 14.6%
for Aβ40.

197

198 Statistical analysis

199 All analyses were conducted using MATLAB (version R2021b) or R statistical software version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org/). In 200 201 general, we utilized the Wilcoxon rank-sum test for two-group comparisons and the Kruskal-202 Wallis test for comparisons involving more than two groups. Spearman's rank correlation was 203 used to measure the strength and direction of association between two continuous variables. 204 For demographic characteristics, continuous variables were presented as mean and standard 205 deviation, while categorical variables were reported as counts. Wilcoxon rank-sum tests and 206 Fisher's exact tests were employed to assess the significance of differences between A+ and A-207 participants for continuous and categorical variables, respectively. Linear mixed models were utilized to assess the association of common AD risk factors, including age, sex, and APOE £4 208 209 carrier status, with biomarkers.

210

The following statistical tests were utilized to explore cross-sectional associations between 211 212 biomarkers and brain Aß and tau pathologies: (1) Wilcoxon rank-sum tests for the univariate 213 significance for the associations between NPQs and dichotomous pathology variables (e.g., A-214 vs. A+), without adjusting for risk factors; (2) Spearman's rank correlation was used to measure 215 the strength and direction of the associations between NPQs and continuous variables (e.g., Aß 216 PET SUVR): (3) linear mixed models (random intercepts) with biomarker NPQs as the 217 dependent variable, visit-specific A β PET status as the independent variables, as well as 218 common risk factors (such as age, sex and APOE ɛ4 carrier status) were used to determine the 219 overall risk factor-adjusted significance combining samples from both visits. False discovery rate 220 corresponding to cutoff p-values were calculated according to the procedure described by Yoav

221 Benjamini and Yosef Hochberg in 1995 [48]. An arbitrary p-value of 0.005 was used as the significance cutoff, which corresponded to 3 to 10% FDR depending on the comparisons. 222 223 Receiver operating characteristic (ROC) curves and the area under curve (AUC) were 224 calculated using the MATLAB perfcurve function, based on scores predicted from generalized 225 linear regression models fitted using the MATLAB *fitglm* function. Confidence intervals were 226 computed using bootstrap with 1000 replicates. DeLong test implemented in the pROC package 227 was used to compare ROC curves [49, 50]. Web app VolcaNoseR was used to create draw the 228 volcano plot [51].

229

230 Longitudinal analysis was limited to participants with plasma samples analyzed at both visits. 231 We calculated the yearly percentage of change for biomarker NPQs and continuous AD 232 pathology variables using this formula: 100 * ([Follow up – Baseline]/[Baseline]) / Δ Time in 233 years. Wilcoxon rank-sum tests were then used for two-group comparisons, and Spearman's 234 rank correlation was used to measure the association between yearly plasma biomarker 235 changes and the yearly AD pathology change. Due to the relatively short duration between the 236 two visits, we did not expect drastic changes in both blood and neuroimaging biomarker levels. 237 Therefore, we treated the longitudinal analysis as explorative, and the original rather than FDR-238 adjusted *p*-values were used to determine significance.

239 Results

240 Cohort characteristics

This study comprised 176 plasma samples from 113 participants (average age 76.7 years at baseline, 54.0% women, and 95.0% non-Hispanic White) from the MYHAT-NI cohort (see Table 1 for demographic characteristics). Among them, 63 participants (55.8%) provided plasma samples at two visits (baseline and the 2-year visit). At baseline, 85 (75.2%) participants were classified as A-negative (A-) and 28 (24.8%) as A-positive (A+), while 42 (66.7%) and 21

(33.3%) were A- and A+, respectively at the 2-year visit. Regarding tau PET, 74 (65.4%)
participants were classified as tau-negative (T-) and 39 (34.5%) as tau-positive (T+) at baseline.
At the 2-year visit, 42 (66.7%) participants were T-, and 21 (33.3%) were T+. In terms of
neurodegeneration according to cortical thickness, 80 (70.8%) participants were considered Nand 33 (29.2%) N+ at baseline, while at the 2-year visit, there were 42 (66.7%) N- and 20
(31.7%) N+ participants. One participant had missing N status at the 2-year visit due to poor
MRI quality.

253

254 Most participants were cognitively normal at both visits. Clinical Dementia Rating (CDR)-based cognitive assessment rated 101 participants (89.3%) as cognitively normal (CDR=0) and 10 255 256 (8.9%) as mildly impaired (CDR=0.5) at baseline. At the 2-year visit, 55 participants (87.2%) 257 were cognitively normal, and 5 (7.9%) were mildly impaired. Two and three participants missed 258 CDR assessments at baseline and the 2-year visit, respectively. Similarly, Mini-Mental State 259 Examination (MMSE) assessment rated 107 (94.6%) participants as cognitively normal (MMSE >=24) and 4 (3.5%) as mildly impaired (MMSE between 19 - 23) at baseline, while all 260 261 participants at the 2-year visit were cognitively normal.

262

263Technical performance and head-to-head comparison of the NULISAseq measurements

with Simoa assays

A total of 116 target assays were incorporated in the NULISAseq CNS disease panel for this study. The plasma concentration range of these targets spanned a minimum of 6 orders of magnitude according to the concentration estimated by mass spectrometry-based proteomics in the Human Protein Atlas database [52, 53]. Despite the broad dynamic ranges of the protein targets, the vast majority exhibited very high detectability, defined as the percentage of samples above the LOD, with a mean ± standard deviation (SD) detectability of 97.2% ± 13.9% (Fig. 1A). Only three targets – UCHL1, PTN, and pTDP43-409 – had detectability below 70%. The 176

272 plasma samples, including 113 baseline and 63 2-year visit samples, were distributed across two plates for NULISAseq measurements. Each plate included two replicates of a pooled 273 274 plasma sample to assess assay reproducibility. The median intra-plate and inter-plate CVs were 275 4.34% (interguartile range [IQR]: 2.80%-6.04%) and 3.11% (IQR: 1.41% -5.45%), respectively, 276 suggesting robust assay reproducibility (Fig. 1B and 1C). Only two targets - CNTN2 and NEFH 277 - had inter-plate CVs greater than 20%, a cutoff commonly used for in vitro diagnostic assays. 278 To assess whether the variation depended on protein abundance, we evaluated the association 279 between the intra- or inter-plate CVs and the abundance ranks for targets (n=46) with plasma 280 concentration data available from the Human Protein Atlas database. As depicted in Fig. 1D and 281 1E, both intra- and inter-plate CVs were not influenced by protein abundance, with p-values for 282 Spearman rank correlations being 0.173 and 0.919, respectively.

283

We next examined the correlation between NULISAseq measurements and Simoa
measurements of selected biomarkers. These included p-tau217, p-tau231, p-tau181, GFAP,
NEFL, Aβ40, and Aβ42. Notably, strong correlations were observed in all pairwise comparisons,
with Spearman rank correlation coefficient (*rho*) values spanning from 0.318 to 0.880 (Fig. 1F).
P-tau217, GFAP, and NEFL demonstrated the strongest between-platform correlation, with *rho*of 0.880, 0.873, and 0.847, respectively.

290

To compare the diagnostic accuracies of the two measurements in detecting A β PET positivity, we calculated the ROC AUCs using logistic regression models in the baseline samples (Table 2). NULISAseq demonstrated comparable performance to Simoa for all seven biomarkers, irrespective of whether common risk factors (age, *APOE* ϵ 4 carrier status, and sex) were included in the models. For example, at baseline, plasma p-tau217 had AUCs of 0.905 (95% CI: 0.841-0.969) on NULISA and 0.880 (95% CI: 0.800-0.959) on Simoa. When accounting for risk factors, these AUCs increased to 0.930 (95% CI: 0.878-0.980) and 0.925 (95% CI: 0.874-

0.977). The DeLong test showed no significant difference between the AUCs. These findings
 suggest that despite its highly multiplexed nature, the NULISAseq platform performs
 equivalently as Simoa for quantifying these biomarkers.

301

302 Association of NULISAseq targets with PET measure of amyloid pathology (A)

303 Cross-sectional association

Several NULISAseq targets showed significant association with the common AD risk factors age, sex, and *APOE* ε 4 carrier status (Additional file 1: Figure S1). To account for the potential confounding effect of these risk factors, we utilized linear mixed models, as described in the "Materials and methods" section, to evaluate the adjusted significance for the cross-sectional association between NULISAseq targets and neuroimaging biomarkers.

309

310 A total of 16 targets showed significant association with A^β pathology, as determined by A^β PET, 311 according to p-value < 0.005, corresponding to approximately 8% FDR (Fig. 2A). Fig. 2B 312 illustrates boxplot distributions of significant targets at baseline and the 2-year visit. NULISAseq 313 plasma p-tau217 demonstrated superior diagnostic accuracy in detecting A^β PET positivity. As 314 stated above, plasma p-tau217 achieved AUCs of 0.905 (95% CI: 0.841-0.969) and 0.922 (95% 315 CI: 0.825-0.972) in the baseline and 2-year visit, respectively, when utilized as the sole 316 predictor. Incorporating common AD risk factors – age, sex, and APOE ε4 carrier status – raised 317 the AUCs to 0.930 (95% CI: 0.878-0.983) and 0.938 (95% CI: 0.856-0.979), respectively. On 318 average, A+ participants exhibited an 82.8% elevation in plasma p-tau217 levels compared to A-319 controls. NULISAseq p-tau231 also exhibited significant association. However, the AUCs and 320 fold increases were inferior to plasma p-tau217. The AUCs were 0.718 (95% CI: 0.615-0.822) in 321 the baseline and 0.698 (95% CI: 0.556-0.821) in the 2-year cohorts based on biomarker-only 322 models, which increased to 0.808 (95% CI: 0.717-0.899) and 0.794 (95% CI: 0.652-0.888)

323 respectively, with the inclusion of common risk factors. An overall 30.7% increase was observed 324 comparing p-tau231 levels in A+ participants to those in A- controls. Moreover, GFAP showed 325 high univariate association prior to adjusting for common risk factors, with Wilcoxon rank-sum p-326 values of 0.0002 for the baseline and 0.006 for the 2-year cohort. However, GFAP showed a strong association with age and APOE £4 carrier status (Additional file 1: Figure S1B and S1C), 327 and its risk factor-adjusted significance weakened to a p-value of 0.016. The fold increase of 328 329 GFAP in A+ vs. A- participants was 45.7%. It distinguished A+ from A- participants with AUCs of 0.732 (95% CI: 0.640-0.825) and 0.715 (95% CI: 0.569-0.830) in the baseline and 2-year 330 331 cohorts based on biomarker-only models, and 0.808 (95% CI: 0.717-0.899) and 0.815 (95% CI: 0.668-0.926), respectively, after adjusting for common risk factors. 332

333

334 Contrarily, the other targets that showed significant associations with AB pathology showed 335 decreased protein levels in the A+ versus A- participants (Fig. 2A and 2B). Metalloproteinase 336 inhibitor 3 (TIMP3), a metalloprotease inhibitor involved in regulating proteostasis [54, 55], 337 exhibited the most substantial decrease in protein levels, with a 60%-fold decrease in A+ vs. A-338 individuals. TIMP3 distinguished A+ and A- participants with AUCs of 0.711 (95%CI: 0.596-339 0.814) and 0.739 (95%CI: 0.574-0.859) for the baseline and 2-year visit cohorts when used as 340 the sole predictor. The inclusion of common risk factors improved the AUCs to 0.850 (95% CI: 341 0.718-0.923) and 0.882 (95% CI: 0.757-0.946). Malate dehydrogenase subunit 1, MDH1, also 342 emerged as one of the top significant proteins, with the risk factor-adjusted p-value < 0.0001, 343 and decreased at an average of 26% in A+ participants. BDNF, a neurotrophic factor with pivotal 344 roles in regulating synaptic plasticity and neuronal survival, showed an overall 42% reduction in 345 A+ participants.

346

347 Six cytokines—IL7, IL13, CD40LG, CCL13, CCL17, and CCL22—were significantly associated
 348 with Aβ pathology, supporting the involvement of immune response and inflammation in AD.

Additional significant targets included SOD1, PGK1, ANXA5, and NULISAseq targets for soluble
 α-synuclein (SNCA) and oligomeric α-synuclein (OligoSNCA).

351

352 Longitudinal association

We then investigated the longitudinal relationship between NULISAseq targets and A β pathology. Three cytokines – FGF2, IL4, and IL9 – exhibited A β PET-dependent yearly percentage changes, with Wilcoxon rank-sum test *p*-values of 0.02, 0.04, and 0.04, respectively (Fig. 3A). The median yearly percentage changes were 9.1%, 1.5%, and 15.4% in A+ individuals, compared to -12.8%, -9.5%, and 0.4% in A- participants, respectively, for FGF2, IL4, and IL9. This means that while the cytokine levels increased over time in A+ individuals, large decreases were recorded for A- participants.

360

Next, we explored the influence of baseline biomarker levels on the progression of Aß 361 pathology, defined as the yearly percentage of change in A^β PET SUVR. Apart from p-tau217, 362 five chemokines - CCL26, CCL17, CCL13, CXCL1, and CXCL8 - demonstrated significant 363 364 associations (Fig. 3B). Higher baseline levels of p-tau217 were associated with more robust 365 increases in A β PET SUVR, with Spearman *rho* of 0.367 (p = 0.003). On the contrary, elevated 366 baseline levels of all five chemokines were linked with a smaller Aβ PET SUVR increase, with 367 *rho* of -0.363 (p = 0.004) for CCL26, -0.343 (p = 0.006) for CCL13, -0.331 (p = 0.008) for 368 CCL17, -0.300 (p = 0.017) for CXCL18, and -0.300 (p = 0.017) for CXCL1. Given that a slower 369 increase in Aß PET SUVR changes is likely indicative of a more favorable prognostic outcome, 370 these findings suggest that higher levels of these chemokines may confer a protective role in 371 recruiting immune cells to attenuate the accumulation of Aß plaques. Consistent with this, all five 372 chemokines were lower in abundance in A+ participants, albeit only CCL13 and CCL17 passed 373 the significance cutoff.

We further tested the association of plasma biomarker longitudinal changes with Aβ PET SUVR changes. Seven NULISAseq targets, namely IL5, p-tau217, Aβ38, PGF, CCL2, IL4, and VEGFD, showed strong correlations (Additional file 1: Figure S2). The changes of all seven targets were positively correlated with Aβ PET SUVR changes, suggesting that upward changes of these targets over time might be correlated with more severe Aβ pathology.

380

381 Association of NULISAseq targets with tau pathology (T)

382 Cross-sectional association

383 Five NULISAseq targets displayed significant associations with tau PET positivity according to 384 p-value cutoff of 0.005, corresponding to FDR of 9%, after adjusting for age, sex and APOE ε4 385 carrier status (Fig. 4A). The three top significant targets were p-tau species, namely p-tau231 (p = 0.0004), p-tau217 (p = 0.0005), and p-tau181 (p = 0.003). SFRP1, a Wnt signaling modulator 386 387 [56], and YWHAG, a member of the 14-3-3 family proteins, were the other significant targets, 388 with p-values of 0.003 and 0.004, respectively. All except SFRP1 were increased in T+ participants. Average fold increases of 29%, 36%, 20%, and 5% in T+ participants compared 389 390 with T- controls were observed for p-tau231, p-tau217, p-tau181, and YWHAG, respectively. 391 SFRP1, on the other hand, was decreased at an average of 27%. Among these five targets, p-392 tau217 had the highest diagnostic accuracy in detecting abnormal tau pathology, with AUCs of 393 0.652 (95% CI: 0.518-0.765) for the baseline cohort and 0.797 (95% CI: 0.660-0.888) for the 2year cohort. This was followed by p-tau231, which had AUCs of 0.651 (95%CI: 0.522-0.759) 394 395 and 0.705 (95% CI: 0.560-0.816), respectively. The inclusion of age, sex, and APOE E4 carrier 396 status only slightly improved the AUCs (Additional file 1: Figure S3). Both p-tau217 and p-397 tau231 showed better diagnostic accuracies in the 2-year cohort, consistent with the expectation 398 that tau pathology worsens over time and that agreement between the plasma and 399 neuroimaging biomarkers improves with disease progression.

400

As indicated in Table 1, there was a higher proportion of A+ individuals among those T+. To test whether the A β PET status contributed to the observed association between these significant targets and tau PET status, we evaluated the association by including A β PET status in the linear mixed models. All remained significant except for p-tau217, which was trending towards significance (p = 0.068) after adjusting for the effect of A β PET status. The *p*-values after adjusting for A β PET status were 0.005, 0.003, 0.005, and 0.001 for p-tau231, p-tau181, SFRP1, and YWHAG, respectively.

408

409 Longitudinal association

410 A total of 17 targets displayed significant tau pathology-dependent longitudinal changes according to the Wilcoxon rank-sum p-value < 0.05 (Fig. 4B). Chitotriosidase-1 (CHIT1), a 411 known indicator of microglial activation [57, 58], emerged as the top significant target (p =412 0.003). Its levels showed slight increases in T- participants, with a median yearly change of 413 2.7%. T+ participants, on the contrary, exhibited a median yearly decrease of 4.4%. Similarly, 414 415 CHI3L1 (YKL-40), a biomarker for reactive astrogliosis, also exhibited an increase (median vearly change of 16.3%) in T- participants but a decrease in T+ individuals (median yearly 416 417 change of -2.8%). These observations suggest that A β pathology may trigger early activation of 418 the brain's immune system to mitigate damage, but this response may plateau or decrease as 419 more downstream pathology, such as tau pathology, becomes apparent. Alternatively, lower glial 420 activation in response to amyloid and tau pathology may reflect the resilience of pathologically 421 burdened but cognitively preserved individuals [59, 60].

422

PGF, PDGFRB, and VEFGA, important players in maintaining cerebrovascular integrity, also
showed tau pathology-dependent longitudinal changes. All three exhibited a declining trend over
time in T+ participants (median yearly change: PGF, -4.1%; PDGFRB, -1.5%; VEGFA, -5.7%),

426 contrasting with either stable or increased levels observed in T- individuals (median yearly 427 change: PGF, -0.6%; PDGFRB, 5.8%; VEFGA, -0.6%). These findings suggest that tau 428 pathology may be linked to the deterioration of vascular structure. NPTX1, a biomarker of 429 excitatory synaptic pathology, similarly displayed a decreasing trend in T+ participants (median -430 4.1%/year), in contrast to a slight upward change in T- controls (median 1.6%/year). Additional 431 targets with tau pathology-dependent longitudinal changes included 4 cytokines (CCL2, CSF2, 432 IL17A, and CX3CL1), proteins involved in synaptic and neuronal dysfunction (VSNL1, CNTN2, 433 and FABP3), IGF1, SLIT2, NEFH, and SQSTM1.

434

Baseline levels of three NULISAseq targets, IL12p70, IFNG, and RUVBL2, were significantly 435 436 associated with tau PET changes between the two visits (Additional file 1: Figure S4A). High 437 baseline levels of IL12p70 and IFNG, two presumptive pro-inflammatory cytokines, were 438 associated with faster progression of tau pathology, as determined by a more pronounced 439 increase in tau PET composite, with *rho* of 0.288 (p = 0.022) and 0.269 (p = 0.033), respectively. The opposite relationship was recorded for RUVBL2, an AAA-type ATPase involved in 440 441 regulating pro-inflammatory response. A higher baseline level of RUVBL2 was associated with a 442 smaller increase in tau pathology, with a rho of -0.253 (p = 0.046).

443

The longitudinal change of seven NULISAseq targets correlated significantly with tau PET SUVR change (Additional file 1: Figure S4B). Interestingly, the list included three tau targets, all of which showed positive associations, namely MAPT (t-tau; *rho* = 0.348; *p* = 0.005), p-tau217 (*rho* = 0.293; *p* = 0.020) and p-tau181 (*rho* = 0.251; *p* = 0.047). Other targets on the list included SOD1 (*rho* = 0.359; *p* = 0.004), IL6R (*rho* = 0.292; *p* = 0.020), CSF2 (*rho* = 0.280; *p* = 0.027), and CD40LG (*rho* = -0.262; *p* = 0.038).

450

451 Association of NULISAseq targets with neurodegeneration (N)

452 Cross-sectional association

453 Twenty NULISAseq targets exhibited significant associations with N status when assessed 454 using univariate analysis with dichotomous outcomes (N- vs. N+) or Spearman correlations with 455 MRI-determined cortical thickness (p-value < 0.005, corresponding to ~ 5% FDR) without adjusting for the effects of common risk factors. The list of significant targets included NEFL, a 456 classical biomarker for neurodegeneration, 8 cytokines (IL2, IL6, IL10, IL16, TNF, CCL3, 457 458 CXCL10, and TAFA5), proteins previously linked to synaptic and neuronal network defects 459 (CALB2, FABP3, and REST), proteins involved in regulating proteostasis (PSEN1, and 460 SQSTM1), proteins involved in acute-phase response (CRP, SAA1 and SAA2), and ICAM1 and 461 VEGFA, both critical for maintaining cerebrovascular integrity. As depicted in the heatmap in Fig. 462 5A, these targets exhibited a consistent trend in both the baseline and 2-year visit samples, with 463 all targets upregulated in N+ individuals compared to N- controls. The repressor element-1 silencing transcription factor (REST), a zinc finger transcription factor with potential 464 465 neuroprotective function [61], was one of the top significant targets, with p-values of 0.004 and 466 0.0008 and AUCs of 0.671 (95% CI 0.561-0.769) and 0.766 (95% CI 0.600-0.883) for the baseline and 2-year visit, respectively (Fig. 5B). NEFL showed a strong association in the 467 468 baseline samples (p = 0.003) but not in the 2-year visit samples (p = 0.126) (Fig. 5B).

469

However, after adjusting for age, sex, and *APOE* ε 4 carrier status, the associations weakened for most of these targets, with SQSTM1 being the only target retaining a *p*-value < 0.005. SQSTM1 exhibited strong association with N status in both baseline and 2-year cohorts, with Wilcoxon rank-sum *p*-values of 0.0001 and 0.006, respectively (Fig. 5B). It distinguished N+ from N- participants with accuracies of 0.729 (95% CI 0.606-0.829) at baseline and 0.713 (95% CI 0.548 -0.854) at the 2-year visit (Fig. 5B). The inclusion of common risk factors (age, sex,

and APOE ε4 carrier status) improved the accuracies to 0.776 (95% CI 0.674-0.860) and 0.848
(95% CI 0.703 -0.933).

478

479 Longitudinal association

480 MME and IL10 demonstrated neurodegeneration-dependent abundance changes, with 481 increases in N+ participants (median change/year: MME, 1.7%; IL10, 9.4%) and decreases in 482 N- individuals (median change/year: MME, 19.2%; IL10, 3.8%) (Fig. 5C).

483

Baseline levels of five NULISAseq targets - KLK6, CCL11, ARGN, TNF, and PGK1 - were 484 485 significantly associated with cortical thickness change, all showing positive correlations, 486 suggesting higher levels of these targets may be linked with a slower rate of neurodegeneration 487 (Additional file 1: Figure S5A). The longitudinal change of five targets – PTN, YWHAZ, GOT1, NRGN, Aβ42, and SNCA (oligomer) – was significantly correlated with cortical thickness change 488 (Additional file 1: Figure S5B), Among them, AB42 exhibited a positive correlation with cortical 489 thickness change, with *rho* of 0.264 (p = 0.037), suggesting that a decrease in A β 42 levels is 490 491 associated with more severe neurodegeneration, i.e., a decrease in cortical thickness. 492 Conversely, changes in the other four targets were negatively associated with cortical thickness 493 change, with *rho* of -0.335 (p = 0.008), -0.291 (p = 0.021), -0.290 (p = 0.022), -0.284 (p = 0.022), 494 0.025), for PTN, YWHAZ, GOT1, and NRGN, respectively.

495

496 Discussion

In this study, we have demonstrated the feasibility of concurrent immunoassay-based analysis
of 116 protein markers in blood to provide diagnostic and prognostic information in preclinical
AD. Our results identified several novel inflammation, synaptic, and vascular markers in blood
significantly associated with brain Aβ, tau, and neurodegeneration burden at baseline and at the

501 two-year follow-up. These were not limited to markers such as p-tau217, p-tau231, p-tau181, and GFAP, the elevation of which have consistently shown strong associations with brain Aß 502 503 and/or tau load but included novel protein targets that inform about the disease state of the 504 individual in different pathological stages across the biological AD continuum. Importantly, this is 505 the first time several of these protein targets have shown validated technical and clinical 506 biomarker potential in blood. These included the cerebrovascular markers ICAM1, VCAM1, 507 PDGFRB, PGF, VEGFA, and VEGFD, the synaptic marker NPTX1, and the glial markers CHIT1 508 and CHI3L1 (YKL-40).

509

510 Concurrent measurement of a large number of protein analytes presents technical challenges 511 that most available immunoassay platforms struggle to address. Problems such as reagent 512 cross-activity and the dynamic range of target analyte abundance impede the multiplexing 513 capacity of immunoassays. Technological breakthroughs, including antibody arrays, proximity 514 ligation assay (PLA), proximity extension assay, microsphere bead capture technology by Luminex, and slow off-rate modified aptamer assay (SOMAscan), have enabled the 515 516 simultaneous measurement of hundreds to thousands of plasma proteins [62]. However, these 517 technologies often use single antibodies that only provide partial information about the protein 518 targets, neglecting ubiquitous post-translational modifications that they undergo in vivo. The 519 NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) technology, which is built as an 520 advancement of the PLA technique, integrates multiple mechanisms to enhance the 521 performance of PLA, including a proprietary sequential immunocomplex capture and release 522 mechanism for background reduction, next-generation sequencing-based signal readout, and 523 fine-tuning the ratio of unconjugated "cold" antibodies to DNA-conjugated "hot" antibodies to 524 mitigate sequencing reads of high-abundant proteins. This provides the proteomic platform the 525 capability to detect hundreds of protein biomarkers with attomolar sensitivity and ultrabroad

dynamic range [34]. The high detectability rate and low detection limits for the various protein
targets in this study support this.

528

The strong correlation and comparable diagnostic accuracies in the head-to-head comparisons with Simoa assays indicate that both techniques measure equivalent pools of the protein targets available in the blood. It is worth mentioning that the exceptional correlation with the Simoa ALZPath assay could be due to the two assays using the same p-tau217 monoclonal antibody.

533

The high performance of plasma p-tau217, p-tau231, and GFAP to identify abnormal A^β PET 534 scans in this mostly cognitively normal cohort is corroborated by findings from several recent 535 536 studies based on results from other analytical platforms [9, 63-67]. Importantly, we identified 537 biomarkers with decreased levels in A+ participants, akin to plasma A\u00df42 and A\u00ef42/40, 538 indicating reduced availability in blood with progressive bran AB pathology. The decreases in 539 TIMP3 are consistent with previously reported lower TIMP3 levels in AD patients [68]. TIMP3 also promotes brain A β production via inhibiting α -secretase cleavage of the amyloid precursor 540 protein [69]. Reduction in MDH1 levels supports previous reports on the involvement of altered 541 energy metabolism in late-onset AD [70, 71] while BDNF has been implicated in a protective 542 543 role against A-induced neurotoxicity [72]. Several studies have also linked multiple inflammatory cytokines to Aβ pathology in AD cases and those resilient to AD [59, 73, 74]. FGF2 gene 544 545 transfer reversed hippocampal function and cognitive decline in mouse models [75]. Similarly, beneficial effects of IL4 have been reported in animal models [75]. 546

547

Plasma p-tau217, p-tau231, and p-tau181 were the leading markers to identify abnormal tau-PET scans. However, accounting for A β PET status in the combined A and T positivity analysis suggested that the results were partly explained by the strong association of these markers with A β pathology. This could mean that the tau forms containing these phosphorylation sites

become available in blood in the early phases of Aβ plaque pathology. Aside from blood-based tau markers, YWHAG [76-78] and SFRP1 [79] showed strong associations with AD. The reduction in SFRP1 levels might be explained by its direct binding to Aβ plaques [80]. Importantly, the existing evidence from these markers has been built in CSF and brain tissue samples. Here, we extend these findings to blood.

557

The reactive astrogliosis marker CHI3L1 (YKL-40) and the microglia activation marker CHIT1 have repeatedly been shown to be associated with tau pathology; however, the evidence base has only been built using CSF samples [6, 81, 82]. The same applies to the vascular markers PGF, PDGFRB, and VEFGA, and the synaptic marker NPTX1, the biomarker potential of which have been demonstrated in CSF [21, 83-89]. Translation of these prior findings to plasma indicates that the molecular processes in AD involving these markers are reflected in the blood stream, expanding the repertoire of blood-based indicators of brain pathophysiological changes.

566 studv identified biomarkers strona association with Our several plasma with a 567 neurodegeneration assessed based on MRI-determined cortical thickness, including NEFL, 568 which is a proven general marker of neuronal injury [90, 91]. Not surprisingly, several cytokines, including IL2, IL6, IL10, IL16, TNF, CCL3, CXCL10, and TAFA5, also showed significant 569 570 association with neurodegeneration, reinforcing relationship the close between neuroinflammation and neurodegenerative processes [92, 93]. 571

572

573 Two vascular proteins, ICAM1 and VEGFA, were on the significant list, consistent with the 574 expected involvement of neurovascular dysfunction in neuroinflammation and 575 neurodegeneration [94]. ICAM1 is a transmembrane glycoprotein expressed in multiple cell 576 types and plays a key role in maintaining the blood brain barrier (BBB) [95]. Its expression is 577 induced by neuroinflammation, leading to increased leukocyte transmigration across the BBB, a

578 pivotal event in the pathogenesis of various brain diseases, including AD [96-98]. Consistent with this, our study observed elevated ICAM1 levels in participants with neurodegeneration, 579 580 aligning with previous research [18, 20]. VEGFs have complex associations with neurological 581 diseases, exhibiting neuroprotective and neuro-destructive potential [24, 25, 99]. We observed 582 elevated VEGFA levels in N+ participants and a faster decline in VEGFA levels in T+ 583 participants, suggesting a potential staging effect. Interestingly, a recent study showed that a 584 low level of VEGFA, measured with assays from Meso Scale Discovery, was associated with 585 accelerated neocortical tau accumulation in preclinical A+ participants in the Harvard Aging 586 Brain Study [100].

587

588 Synaptic and neuronal network dysfunction, along with aberrant proteostasis, represent two of 589 the eight pathological hallmarks of neurodegenerative diseases [35]. In alignment with this, our 590 study found significant associations between neurodegeneration, three synaptic/network 591 proteins (CALB2, FABP3, and REST), and two proteostatic regulators (PSEN1 and SQSTM1). 592 Notably, among all targets with significant association with neurodegeneration, only SQSTM1 593 withstood corrections for age, sex, and APOE ε 4 genotype, revealing it as a potentially novel 594 neurodegeneration biomarker for AD. SQSTM1, a scaffold protein with a critical role in 595 macroautophagy, has been previously linked to several neurodegenerative diseases, including 596 AD [101-103].

597

IL10 and MME were the top hits with differential longitudinal change in N+ vs. N- participants. Several studies support their roles as markers of neurodegeneration status. For example, an animal model study suggested that the mechanisms of action of IL-10 as an inflammatory response might be through the activation of microglia, which leads to IL-6 activation and abnormal phosphorylation of tau [104]. MME, also known as neprilysin, is an integral membrane-bound metallopeptidase (MMP) and one of the key enzymes involved in Aβ

degradation [105]. MMPs have been found to exhibit dual roles in AD pathogenesis. On the one
hand, they can reduce the amount of Aβ deposits by degrading Aβ peptides [106, 107]. On the
other hand, their levels can be induced by Aβ, potentially leading to brain parenchymal
destruction [108, 109]. Interestingly, in addition to demonstrating significant longitudinal changes
between N+ and N- participants, MME exhibited lower levels in A+ participants compared to Acontrols, yet higher levels in N+ participants compared to N-, supporting its potential utility as a
staging biomarker for AD.

611

Interestingly, while a number of cytokines (IL2, IL6, IL10, IL16, TNF, CCL3, CXCL10, and 612 613 TAFA5) were increased in participants with neurodegeneration, several cytokines (IL7, IL13, 614 CD40LG, CCL13, CCL17, and CCL22) were found to be decreased in participants with Aß 615 pathology. Additionally, higher baseline levels of several chemokines (CCL26, CCL17, CCL13, 616 CXCL1, and CXCL8) were significantly associated with slower progression of AB pathology. 617 Given that most participants with A^β pathology were cognitively normal, and neurodegeneration 618 is presumed to occur at a later stage than the early phase of AB pathology, our results support 619 the biphasic roles of neuroinflammation, with protective effects in the early stages and 620 potentially detrimental effects in the later stages. These findings are in line with the recognized 621 multifaceted impact of neuroinflammation on AD pathogenesis [110, 111].

622

Strengths of this study include (i) technical validation of the new NULISA platform; (ii) direct comparison of the clinical performances of biomarkers measured using NULISA assays vs. with Simoa assays; (iii) focus on a population-based cohort to provide information closer to the real world than most clinical research-based cohorts; (iv) emphasis on predominantly cognitively normal participants with emerging pathological phenotypes, to test the sensitivity of the NULISA platform to these incipient changes; (v) availability of paired neuroimaging measures of $A\beta$, tau, and neurodegeneration, making it possible to identify inflammatory, vascular and synaptic

630 markers associated with abnormal changes in different biologically defined disease stages; and 631 (vi) repeated neuroimaging evaluations and blood collection over a two-year interval, allowing to 632 examine biomarker changes within that timeframe. Limitations include the lack of validation in 633 diverse cohorts.

634 **Conclusions**

Together, this targeted proteomic study has established that results from the NULISA platform 635 are equivalent to those from Simoa HDX. Additionally, the strong multiplexing capabilities of 636 637 NULISA allowed for the evaluation of dozens of verified and putative protein biomarkers in a 638 longitudinal preclinical AD cohort. We identified several neuroinflammation, synaptic, and 639 vascular markers that have been previously linked to AD, but their measurement in plasma was hitherto not established. Our findings, therefore, pave the way for independent validation of 640 641 these plasma markers to enable their widespread use for diagnostic, prognostic, and 642 monitoring.

643 **Abbreviations**

644	Αβ	Amyloid-beta
645	AD	Alzheimer's disease
646	AUC	Area under Curve
647	BBB	Blood brain barrier
648	CDR	Clinical dementia rating
649	CNS	Central nervous system
650	CSF	Cerebrospinal fluid
651	CV	Coefficient of variation
652	FDR	False discovery rate
653	IC	Internal control
654	IQR	Interguartile range

- 655 LOD Limit of detection
- 656 MCI Mild cognitive impairment
- 657 MMSE Mini-Mental State Examination
- 658 MRI Magnetic resonance imaging
- 659 MYHAT Monongahela Youghiogheny Healthy Aging Team
- 660 MYHAT NI Monongahela Youghiogheny Healthy Aging Team-Neuroimaging
- 661 NPQ NULISA protein quantification
- 662 NULISA NUcleic acid-linked Immuno-Sandwich Assay
- 663 NULISAseq NULISA with next-generation sequencing readout
- 664 PiB Pittsburgh compound-B
- 665 PLA Proximity ligation assay
- 666 p-tau Phosphorylated tau
- 667 PET Positron emission tomography
- 668 QC Quality control
- 669 ROC Receiver operating characteristic
- 670 ROIs Regions of interest
- 671 SD Standard deviation
- 672 Simoa Single-molecule array
- 673 SUVR Standardized uptake value ratio
- 674

675 Acknowledgments

- 676 We thank all members of the Karikari Laboratory and Dr. Rebecca Deek for statistical advice.
- 677 We are indebted to the participants, family members, and staff of the MYHAT-NI study.

678 Author contributions

TKK, MIK, ADC, BES, and MG contributed to the study's conception and design. BES and MG ran MYHAT and MYHAT-NI cohorts. ADC, VLV, TAP, PCLF, BB, GP, OIL and WEK contributed to neuroimaging data collection and analysis. TKL, AS, PCF, BB, and PG performed biochemical assays. MIK performed genotyping experiments. XZ and YC performed data analysis and produced the figures. XZ and TKK were major contributors in writing the manuscript. All authors contributed to and approved the final version of the manuscript.

685

686 Funding

TKK was supported by the NIH (R01 AG083874, U24 AG082930, P30 AG066468, RF1
AG052525-01A1, R01 AG053952-05, R37 AG023651-17, RF1 AG025516-12A1, R01
AG073267-02, R01 AG075336-01, R01 AG072641-02, P01 AG025204-16) and the Alzheimer's
Association (#AARF-21-850325). MDI was supported by NIH/NIA grants P01AG14449 and
P01AG025204. The MYHAT study was supported by R37 AG023651-17 and MYHAT-NI by R01
AG052521.

693 **Data availability**

De-identified, cohort-level data will be shared at the request of verified investigators to replicate procedures and results reported in this article. Data transfer agreements in accordance with US legislation and the decisions of the University of Pittsburgh's Institutional Review Board, which covers the jurisdiction of the MYHAT-NI study, may need to be established.

698 **Declarations**

699 Ethics approval and consent to participate

- All plasma samples were obtained with full written informed consent and approved by the
- 701 University of Pittsburgh Institutional Review Board (STUDY19020264).
- 702 **Consent for publication**
- 703 Not applicable.
- 704 Competing interest
- The authors declare that they have no competing interests

706 Supplementary Information

• Additional file 1: Supplementary Figure S1 to S5

708

709 Tables

- **Table 1:** Participant characteristics in the MYHAT-NI cohort
- Table 2: Diagnostic accuracy (ROC analysis) of NULISAseq and Simoa biomarkers for
 Aβ PET positivity.

713

714 Figure legends

715 Fig. 1: Performance of the NULISAseq CNS disease panel. A Box plots illustrating the 716 detectability of 116 targets in 176 plasma samples collected from 113 MYHAT-NI participants. 717 The y-axis represents NPQ - LOD, where values >0 indicate detectability. On each box, the 718 central mark indicates the median, and the bottom and top edges of the box indicate the 25th 719 and 75th percentiles, respectively. The whiskers extend to the most extreme data points not considered outliers, and the outliers are plotted individually using the '+' marker symbol. Data 720 points were considered outliers if they were greater than $q3 + 1.5 \times (q3 - q1)$ or less than q1 - q1721 722 $1.5 \times (q_3 - q_1)$, where q1 and q3 are the 25th and 75th percentiles of the sample data. **B-C**

723 Histogram distribution of intra-plate (B) and inter-plate (C) coefficient of variations (CVs). D-E 724 Scatterplot distributions between abundance rank and intra-plate (D) or inter-plate (E) CVs. 725 Intra- and inter-plate CVs were calculated based on results of a pooled plasma sample (SC), 726 measured in duplicate each in two different plates. Abundance rank was based on the mass 727 spectrometry-estimated protein abundance in the Human Protein Atlas (downloaded on 728 12/24/2023). (F) Scatterplot distributions illustrating the correlation of protein levels measured 729 using NULISAseq and Simoa method. Rho and p values were determined using Spearman 730 rank-based correlation. Purple lines indicated the least square regression lines. NPQ. NULISA Protein Quantification; LOD, limit of detection. 731

732 Fig. 2: Cross-sectional association of NULISAseq targets with amyloid pathology (A). A Volcano plot of -log10(p-value) versus log2(fold change) comparing biomarker abundances (NPQ) in 733 734 samples from A+ participants (n=49) vs. A- controls (n=127). Significant targets are shown in 735 red (higher in A+) or blue (lower in A+) circles. Grey circles represent non-significant targets. B 736 Boxplot distributions of significant NULISAseq targets, separated by A status and visit. P-values 737 on top of the boxplots were for the whole data combining both visits and were determined using linear mixed models (random intercepts) with NPQs as the dependent variable, visit-specific A 738 739 status as the independent variables, adjusting for covariates age, sex, and APOE E4 carrier 740 status. Significance determination was based on p-value < 0.005, corresponding to ~8% FDR.

Fig. 3: Longitudinal association between NULISAseq targets and amyloid pathology (A). A Boxplots illustrating the distribution of yearly biomarker abundance change by A status. P-values were based on two-sided Wilcoxon rank sum tests. B Scatterplots for the correlation between yearly longitudinal Aβ PET SUVR change and baseline biomarker levels. The strength of the correlation was assessed based on Spearman's ranks. Purple lines indicated the least square regression lines.

747 Fig. 4: Association of NULISAseg targets with tau pathology (T). A Boxplots of NULISAseg 748 targets with significant cross-sectional associations with T status, separated by T status and visit. P-values on top of the boxplots were for the whole data combining both visits and were 749 750 determined using linear mixed models (random intercepts) with NPQs as the dependent 751 variable, visit-specific T status as the independent variables, adjusting for covariates age, sex 752 and APOE $\varepsilon 4$ carrier status. Significance determination was based on p-value < 0.005. 753 corresponding to ~9% FDR. B Boxplots illustrating the distribution of yearly biomarker 754 abundance change by T status. P-values were based on two-sided Wilcoxon rank sum tests.

755 Fig. 5: Association of NULISAseq targets with neurodegeneration (N). A Heatmaps illustrating 756 the abundance levels of NULISAseg with significant univariate association with N status 757 (unadjusted for covariates). The NPQ values were standardized for each protein target using z-758 scores. B Boxplots of selected NULISAseq targets, separated by N status and visit. P-values on 759 top of the boxplots were for the whole data combining both visits and were determined using 760 linear mixed models (random intercepts) with NPQs as the dependent variable, visit-specific N 761 status as the independent variables, adjusting for covariates age, sex, and APOE E4 carrier 762 status. C Boxplots illustrating the distribution of yearly biomarker abundance change by N status. P-values were based on two-sided Wilcoxon rank sum tests. 763

764

765 **References**

1. Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's

767 Association Workgroup [https://aaic.alz.org/diagnostic-criteria.asp]

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM,
 Jagust W, Jessen F, Karlawish J, et al: NIA-AA Research Framework: Toward a

770		biological definition of Alzheimer's disease. Alzheimer's & Dementia 2018, 14:535-
771		562.
772	3.	Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
773	4.	Masliah E: Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol
774		Histopathol 1995, 10: 509-519.
775	5.	Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M,
776		Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, et al: Changes in Synaptic
777		Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease
778		Cerebrospinal Fluid. Mol Cell Proteomics 2019, 18:546-560.
779	6.	Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang Y-T, Leffa DT, Brum WS,
780		Benedet AL, Ashton NJ, De Bastiani MA, et al: Astrocyte biomarker signatures of
781		amyloid-β and tau pathologies in Alzheimer's disease. Molecular Psychiatry 2022,
782		27: 4781-4789.
783	7.	Pelkmans W, Shekari M, Brugulat-Serrat A, Sánchez-Benavides G, Minguillón C, Fauria
784		K, Molinuevo JL, Grau-Rivera O, González Escalante A, Kollmorgen G, et al: Astrocyte
785		biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.
786		Alzheimer's & Dementia 2024, 20: 483-493.
787	8.	Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R,
788		Molinuevo JL: Cerebrospinal fluid level of YKL-40 protein in preclinical and
789		prodromal Alzheimer's disease. J Alzheimers Dis 2014, 42:901-908.
790	9.	Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE,
791		Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O: Plasma GFAP is an early
792		marker of amyloid- β but not tau pathology in Alzheimer's disease. Brain 2021,
793		144: 3505-3516.
794	10.	Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque
795		Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, et al: Early

796		increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-
797		neurodegeneration but not with amyloid- β pathology. Molecular Neurodegeneration
798		2019, 14: 1.
799	11.	Park S-H, Lee E-H, Kim H-J, Jo S, Lee S, Seo SW, Park H-H, Koh S-H, Lee J-H: The
800		relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's
801		disease. Scientific Reports 2021, 11:13050.
802	12.	Rauchmann B-S, Schneider-Axmann T, Alexopoulos P, Perneczky R: CSF soluble
803		TREM2 as a measure of immune response along the Alzheimer's disease
804		continuum. Neurobiology of Aging 2019, 74:182-190.
805	13.	Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P,
806		Öhrfelt A, Blennow K, Hardy J, Schott J, et al: Increased cerebrospinal fluid soluble
807		TREM2 concentration in Alzheimer's disease. Molecular Neurodegeneration 2016,
808		11: 3.
809	14.	Hok AHYS, Del Campo M, Boiten WA, Stoops E, Vanhooren M, Lemstra AW, van der
810		Flier WM, Teunissen CE: Neuroinflammatory CSF biomarkers MIF, sTREM1, and
811		sTREM2 show dynamic expression profiles in Alzheimer's disease. J
812		Neuroinflammation 2023, 20:107.
813	15.	Motta C, Finardi A, Toniolo S, Di Lorenzo F, Scaricamazza E, Loizzo S, Mercuri NB,
814		Furlan R, Koch G, Martorana A: Protective Role of Cerebrospinal Fluid Inflammatory
815		Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early
816		Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. Journal of Alzheimer's
817		<i>Disease</i> 2020, 76: 681-689.
818	16.	Doroszkiewicz J, Kulczynska-Przybik A, Dulewicz M, Borawska R, Krawiec A, Slowik A,
819		Mroczko B: The cerebrospinal fluid interleukin 8 (IL-8) concentration in Alzheimer's
820		disease (AD). Alzheimer's & Dementia 2021, 17:e051317.

821	17.	Taipa R, das Neves SP, Sousa AL, Fernandes J, Pinto C, Correia AP, Santos E, Pinto
822		PS, Carneiro P, Costa P, et al: Proinflammatory and anti-inflammatory cytokines in
823		the CSF of patients with Alzheimer's disease and their correlation with cognitive
824		decline. Neurobiology of Aging 2019, 76:125-132.
825	18.	Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K,
826		Hansson O: CSF biomarkers of neuroinflammation and cerebrovascular
827		dysfunction in early Alzheimer disease. Neurology 2018, 91:e867-e877.
828	19.	Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, Zetterberg
829		H, Blennow K, Carlsson CM, Neuhaus J, et al: Cerebrospinal Fluid and Plasma
830		Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's
831		Disease Pathology and Neuronal Damage. Journal of Alzheimer's Disease 2018,
832		62: 385-397.
833	20.	Rauchmann B-S, Sadlon A, Perneczky R, for the Alzheimer's Disease Neuroimaging I:
834		Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal
835		Fluid. Journal of Alzheimer's Disease 2020, 73:1615-1626.
836	21.	Miners JS, Kehoe PG, Love S, Zetterberg H, Blennow K: CSF evidence of pericyte
837		damage in Alzheimer's disease is associated with markers of blood-brain barrier
838		dysfunction and disease pathology. Alzheimer's Research & Therapy 2019, 11:81.
839	22.	Wang J, Fan D-Y, Li H-Y, He C-Y, Shen Y-Y, Zeng G-H, Chen D-W, Yi X, Ma Y-H, Yu J-T,
840		Wang Y-J: Dynamic changes of CSF sPDGFR β during ageing and AD progression
841		and associations with CSF ATN biomarkers. Molecular Neurodegeneration 2022,
842		17: 9.
843	23.	Lv X, Zhang M, Cheng Z, Wang Q, Wang P, Xie Q, Ni M, Shen Y, Tang Q, Gao F, China
844		Aging Neurodegenerative Disorder Initiative C: Changes in CSF sPDGFR β level and
845		their association with blood-brain barrier breakdown in Alzheimer's disease with

846		or without small cerebrovascular lesions. Alzheimer's Research & Therapy 2023,
847		15: 51.
848	24.	Storkebaum E, Carmeliet P: VEGF: a critical player in neurodegeneration. J Clin
849		Invest 2004, 113: 14-18.
850	25.	Garcia KO, Ornellas FL, Martin PK, Patti CL, Mello LE, Frussa-Filho R, Han SW, Longo
851		BM: Therapeutic effects of the transplantation of VEGF overexpressing bone
852		marrow mesenchymal stem cells in the hippocampus of murine model of
853		Alzheimer's disease. Front Aging Neurosci 2014, 6:30.
854	26.	Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, Vanbrabant J, Jacobs D,
855		Vanderstichele H, Vanmechelen E, et al: Synaptic biomarkers in CSF aid in
856		diagnosis, correlate with cognition and predict progression in MCI and
857		Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical
858		Interventions 2019, 5: 871-882.
859	27.	Dulewicz M, Kulczyńska-Przybik A, Słowik A, Borawska R, Mroczko B: Neurogranin
860		and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in
861		Alzheimer's Disease. Journal of Clinical Medicine 2021, 10:4575.
862	28.	Libiger O, Shaw LM, Watson MH, Nairn AC, Umaña KL, Biarnes MC, Canet-Avilés RM,
863		Jack Jr. CR, Breton Y-A, Cortes L, et al: Longitudinal CSF proteomics identifies
864		NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimer's & Dementia
865		2021, 17: 1976-1987.
866	29.	Pilotto A, Bongianni M, Tirloni C, Galli A, Padovani A, Zanusso G: CSF alpha-synuclein
867		aggregates by seed amplification and clinical presentation of AD. Alzheimer's &
868		Dementia 2023, 19: 3754-3759.
869	30.	Anderson NL, Anderson NG: The Human Plasma Proteome: History, Character, and
870		Diagnostic Prospects*. Molecular & Cellular Proteomics 2002, 1:845-867.

871	31.	Galasko D, Golde TE: Biomarkers for Alzheimer's disease in plasma, serum and
872		blood - conceptual and practical problems. Alzheimer's Research & Therapy 2013,
873		5: 10.
874	32.	Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N,
875		Kornhuber J, Hansson O, Minthon L, Spitzer P, et al: Characterization of the
876		postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma
877		samples from Alzheimer's disease patients and healthy controls. Alzheimers Res
878		<i>Ther</i> 2015, 7: 40.
879	33.	De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, Andreasson U, De
880		Surgeloose D, Hernalsteen D, Sleegers K, et al: C-terminal neurogranin is increased
881		in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimer's
882		& Dementia 2015, 11: 1461-1469.
883	34.	Feng W, Beer JC, Hao Q, Ariyapala IS, Sahajan A, Komarov A, Cha K, Moua M, Qiu X,
884		Xu X, et al: NULISA: a proteomic liquid biopsy platform with attomolar sensitivity
885		and high multiplexing. Nature Communications 2023, 14:7238.
886	35.	Wilson DM, 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM,
887		Dewachter I: Hallmarks of neurodegenerative diseases. Cell 2023, 186:693-714.
888	36.	Sullivan KJ, Liu A, Chang CH, Cohen AD, Lopresti BJ, Minhas DS, Laymon CM, Klunk
889		WE, Aizenstein H, Nadkarni NK, et al: Alzheimer's disease pathology in a
890		community-based sample of older adults without dementia: The MYHAT
891		neuroimaging study. Brain Imaging Behav 2021, 15:1355-1363.
892	37.	Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC: Mild cognitive impairment:
893		incidence and vascular risk factors in a population-based cohort. Neurology 2013,
894		80: 2112-2120.

895	38.	Ganguli M, Chang CC, Snitz BE, Saxton JA, Vanderbilt J, Lee CW: Prevalence of mild
896		cognitive impairment by multiple classifications: The Monongahela-Youghiogheny
897		Healthy Aging Team (MYHAT) project. Am J Geriatr Psychiatry 2010, 18:674-683.
898	39.	Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules.
899		Neurology 1993, 43: 2412-2414.
900	40.	Kamboh MI, Fan KH, Yan Q, Beer JC, Snitz BE, Wang X, Chang CH, Demirci FY,
901		Feingold E, Ganguli M: Population-based genome-wide association study of
902		cognitive decline in older adults free of dementia: identification of a novel locus
903		for the attention domain. Neurobiol Aging 2019, 84:239.e215-239.e224.
904	41.	Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M,
905		Savitcheva I, Huang GF, Estrada S, et al: Imaging brain amyloid in Alzheimer's
906		disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
907	42.	Lopez OL, Becker JT, Chang Y, Klunk WE, Mathis C, Price J, Aizenstein HJ, Snitz B,
908		Cohen AD, DeKosky ST, et al: Amyloid deposition and brain structure as long-term
909		predictors of MCI, dementia, and mortality. Neurology 2018, 90:e1920-e1928.
910	43.	Snitz BE, Tudorascu DL, Yu Z, Campbell E, Lopresti BJ, Laymon CM, Minhas DS,
911		Nadkarni NK, Aizenstein HJ, Klunk WE, et al: Associations between NIH Toolbox
912		Cognition Battery and in vivo brain amyloid and tau pathology in non-demented
913		older adults. Alzheimers Dement (Amst) 2020, 12:e12018.
914	44.	Baker SL, Maass A, Jagust WJ: Considerations and code for partial volume
915		correcting [(18)F]-AV-1451 tau PET data. Data Brief 2017, 15:648-657.
916	45.	Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust
917		WJ: Comparison of multiple tau-PET measures as biomarkers in aging and
918		Alzheimer's disease. Neuroimage 2017, 157:448-463.
919	46.	Gogola A, Lopresti BJ, Tudorascu D, Snitz B, Minhas D, Doré V, Ikonomovic MD,
920		Shaaban CE, Matan C, Bourgeat P, et al: Biostatistical Estimation of Tau Threshold

921 Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies. Journal of

- 922 *Nuclear Medicine* 2023:jnumed.123.265941.
- 47. Jack CR, Jr., Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL,
- 924 Senjem ML, Jones DT, Kantarci K, et al: **Defining imaging biomarker cut points for**
- brain aging and Alzheimer's disease. *Alzheimers Dement* 2017, **13**:205-216.
- 48. Benjamini Y, Hochberg Y: **Controlling the False Discovery Rate: A Practical and**
- 927 **Powerful Approach to Multiple Testing.** Journal of the Royal Statistical Society: Series
- 928 *B (Methodological)* 1995, **57:**289-300.
- 49. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or
- 930 more correlated receiver operating characteristic curves: a nonparametric
- 931 **approach.** *Biometrics* 1988, **44:**837-845.
- 50. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M: **pROC: an**
- open-source package for R and S+ to analyze and compare ROC curves. BMC
 Bioinformatics 2011, 12:77.
- 935 51. Goedhart J, Luijsterburg MS: VolcaNoseR is a web app for creating, exploring,

936 **labeling and sharing volcano plots.** *Scientific Reports* 2020, **10:**20560.

- 937 52. Uhlen M, Karlsson MJ, Zhong W, Tebani A, Pou C, Mikes J, Lakshmikanth T, Forsström
- B, Edfors F, Odeberg J, et al: A genome-wide transcriptomic analysis of protein-
- coding genes in human blood cells. Science 2019, 366.
- 53. Uhlén M, Karlsson MJ, Hober A, Svensson AS, Scheffel J, Kotol D, Zhong W, Tebani A,
- 941 Strandberg L, Edfors F, et al: **The human secretome.** *Sci Signal* 2019, **12**.
- 942 54. Apte SS, Olsen BR, Murphy G: The gene structure of tissue inhibitor of
- 943 metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP
- 944 **gene family.** *J Biol Chem* 1995, **270**:14313-14318.

945	55.	Costa S, Ragusa MA, Lo Buglio G, Scilabra SD, Nicosia A: The Repertoire of Tissue
946		Inhibitors of Metalloproteases: Evolution, Regulation of Extracellular Matrix
947		Proteolysis, Engineering and Therapeutic Challenges. Life 2022, 12:1145.
948	56.	Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, Cumberledge S,
949		Rubin JS: Secreted frizzled-related protein-1 binds directly to Wingless and is a
950		biphasic modulator of Wnt signaling. J Biol Chem 2000, 275:4374-4382.
951	57.	Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek
952		A, Diehl-Schmid J, Fassbender K, et al: Chitotriosidase (CHIT1) is increased in
953		microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and
954		cerebrospinal fluid levels correlate with disease severity and progression. J Neurol
955		Neurosurg Psychiatry 2018, 89:239-247.
956	58.	Varghese AM, Ghosh M, Bhagat SK, Vijayalakshmi K, Preethish-Kumar V, Vengalil S,
957		Chevula P-C-R, Nashi S, Polavarapu K, Sharma M, et al: Chitotriosidase, a biomarker
958		of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor
959		neurons through neuroinflammation. Journal of Neuroinflammation 2020, 17:232.
960	59.	Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M,
961		Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ, et al: Distinct cytokine
962		profiles in human brains resilient to Alzheimer's pathology. Neurobiol Dis 2019,
963		121: 327-337.
964	60.	Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I,
965		Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, et al: Dissecting
966		phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 2013,
967		136: 2510-2526.
968	61.	Hwang JY, Zukin RS: REST, a master transcriptional regulator in neurodegenerative

disease. *Curr Opin Neurobiol* 2018, **48:**193-200.

970	62.	Ren AH, Diamandis EP, Kulasingam V: Uncovering the Depths of the Human
971		Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein
972		Detection and Quantification. Mol Cell Proteomics 2021, 20:100155.
973	63.	Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE,
974		Cody K, Wilson R, Carlsson CM, et al: Diagnostic Accuracy of a Plasma
975		Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA
976		Neurology 2024, 81: 255-263.
977	64.	Triana-Baltzer G, Moughadam S, Slemmon R, Van Kolen K, Theunis C, Mercken M,
978		Kolb HC: Development and validation of a high-sensitivity assay for measuring
979		p217+tau in plasma. Alzheimer's & Dementia: Diagnosis, Assessment & Disease
980		Monitoring 2021, 13: e12204.
981	65.	Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, Kolb HC,
982		Ossenkoppele R, Janelidze S, Hansson O: Diagnostic and prognostic performance
983		to detect Alzheimer's disease and clinical progression of a novel assay for plasma
984		p-tau217. Alzheimer's Research & Therapy 2022, 14:67.
985	66.	Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G,
986		Snellman A, Schöll M, Troakes C, Hye A, et al: Plasma p-tau231: a new biomarker for
987		incipient Alzheimer's disease pathology. Acta Neuropathol 2021, 141:709-724.
988	67.	Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L,
989		Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, et al: Plasma p-tau231
990		and p-tau217 as state markers of amyloid- β pathology in preclinical Alzheimer's
991		disease. Nature Medicine 2022, 28:1797-1801.
992	68.	Park JH, Cho S-J, Jo C, Park MH, Han C, Kim E-J, Huh GY, Koh YH: Altered TIMP-3
993		Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's
994		Disease. Journal of Personalized Medicine 2022, 12:827.

- 995 69. Hoe HS, Cooper MJ, Burns MP, Lewis PA, van der Brug M, Chakraborty G, Cartagena
- 996 CM, Pak DT, Cookson MR, Rebeck GW: The metalloprotease inhibitor TIMP-3
- 997 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J
- 998 *Neurosci* 2007, **27**:10895-10905.
- 999 70. Jia D, Wang F, Yu H: Systemic alterations of tricarboxylic acid cycle enzymes in
- 1000 Alzheimer's disease. Front Neurosci 2023, **17**:1206688.
- 1001 71. Sonntag K-C, Ryu W-I, Amirault KM, Healy RA, Siegel AJ, McPhie DL, Forester B,
- Cohen BM: Late-onset Alzheimer's disease is associated with inherent changes in
 bioenergetics profiles. *Scientific Reports* 2017, 7:14038.
- 1004 72. Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, Yao XQ, Zhang LL, Zhou HD, Walker
- 1005 DG, et al: Brain-derived neurotrophic factor protects against tau-related
- neurodegeneration of Alzheimer's disease. *Translational Psychiatry* 2016, 6:e907 e907.
- 1008 73. Wojcieszak J, Kuczyńska K, Zawilska JB: Role of Chemokines in the Development
 1009 and Progression of Alzheimer's Disease. J Mol Neurosci 2022, 72:1929-1951.
- 1010 74. Wharton W, Kollhoff AL, Gangishetti U, Verble DD, Upadhya S, Zetterberg H, Kumar V,
- Watts KD, Kippels AJ, Gearing M, et al: Interleukin 9 alterations linked to alzheimer
 disease in african americans. *Ann Neurol* 2019, 86:407-418.
- 1013 75. Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T: **FGF2 gene transfer restores**
- 1014 hippocampal functions in mouse models of Alzheimer's disease and has
- 1015therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A
- 1016 2011, **108:**E1339-1348.
- 1017 76. Sathe G, Na CH, Renuse S, Madugundu AK, Albert M, Moghekar A, Pandey A:
- 1018
 Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate
- 1019 **Biomarkers for Alzheimer's Disease.** *PROTEOMICS Clinical Applications* 2019,
- 1020 **13**:1800105.

1021	77.	Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, Ping L, Duong
1022		DM, Epstein MP, McDade E, et al: Cerebrospinal fluid proteomics define the natural
1023		history of autosomal dominant Alzheimer's disease. Nature Medicine 2023,
1024		29: 1979-1988.
1025	78.	Bader JM, Geyer PE, Müller JB, Strauss MT, Koch M, Leypoldt F, Koertvelyessy P,
1026		Bittner D, Schipke CG, Incesoy EI, et al: Proteome profiling in cerebrospinal fluid
1027		reveals novel biomarkers of Alzheimer's disease. Molecular Systems Biology 2020,
1028		16: e9356.
1029	79.	Esteve P, Rueda-Carrasco J, Inés Mateo M, Martin-Bermejo MJ, Draffin J, Pereyra G,
1030		Sandonís Á, Crespo I, Moreno I, Aso E, et al: Elevated levels of Secreted-Frizzled-
1031		Related-Protein 1 contribute to Alzheimer's disease pathogenesis. Nat Neurosci
1032		2019, 22: 1258-1268.
1033	80.	Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, Yarbro JM, Han X, Lutz BM, Rao S, et al:
1034		Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's
1035		Disease Progression. Neuron 2020, 105:975-991.e977.
1036	81.	Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P,
1037		Baiardi S, Zenesini C, Huss A, Cortelli P, et al: CSF biomarkers of neuroinflammation
1038		in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res
1039		<i>Ther</i> 2019, 12: 2.
1040	82.	Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, Teipel S, Cavedo E,
1041		dos Santos AM, Epelbaum S, et al: Two-level diagnostic classification using
1042		cerebrospinal fluid YKL-40 in Alzheimer's disease. Alzheimer's & Dementia 2017,
1043		13 :993-1003.
1044	83.	Tubi MA, Kothapalli D, Hapenney M, Feingold FW, Mack WJ, King KS, Thompson PM,
1045		Braskie MN: Regional relationships between CSF VEGF levels and Alzheimer's

1046 disease brain biomarkers and cognition. *Neurobiol Aging* 2021, **105**:241-251.

1047	84.	De Kort AM, Kuiperij HB, Kersten I, Versleijen AAM, Schreuder F, Van Nostrand WE,
1048		Greenberg SM, Klijn CJM, Claassen J, Verbeek MM: Normal cerebrospinal fluid
1049		concentrations of PDGFR eta in patients with cerebral amyloid angiopathy and
1050		Alzheimer's disease. Alzheimers Dement 2022, 18:1788-1796.
1051	85.	Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM,
1052		Zetterberg H, Blennow K: Synaptic proteins in CSF as potential novel biomarkers
1053		for prognosis in prodromal Alzheimer's disease. Alzheimer's Research & Therapy
1054		2018, 10: 5.
1055	86.	Cicognola C, Mattsson-Carlgren N, van Westen D, Zetterberg H, Blennow K, Palmqvist
1056		S, Ahmadi K, Strandberg O, Stomrud E, Janelidze S, Hansson O: Associations of CSF
1057		PDGFR β With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and
1058		Alzheimer Disease Pathologic Changes. Neurology 2023, 101:e30-e39.
1059	87.	Wang Y, Emre C, Gyllenhammar-Schill H, Fjellman K, Eyjolfsdottir H, Eriksdotter M,
1060		Schultzberg M, Hjorth E: Cerebrospinal Fluid Inflammatory Markers in Alzheimer's
1061		Disease: Influence of Comorbidities. Curr Alzheimer Res 2021, 18:157-170.
1062	88.	Sudduth TL, Winder Z, Elahi FM, Nelson PT, Jicha GA, Wilcock DM: CSF and plasma
1063		placental growth factor as a biomarker for small-vessel damage in VCID.
1064		Alzheimer's & Dementia 2021, 17: e052995.
1065	89.	Hinman JD, Elahi F, Chong D, Radabaugh H, Ferguson A, Maillard P, Thompson JF,
1066		Rosenberg GA, Sagare A, Moghekar A, et al: Placental growth factor as a sensitive
1067		biomarker for vascular cognitive impairment. Alzheimers Dement 2023, 19:3519-
1068		3527.
1069	90.	Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet
1070		AL, Pascoal TA, Lleó A, Parnetti L, et al: A multicentre validation study of the
1071		diagnostic value of plasma neurofilament light. Nature Communications 2021,
1072		12: 3400.

1073 91. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Group atN:

- 1074 Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology:
- 1075 A Systematic Review and Meta-analysis. JAMA Neurology 2019, 76:1035-1048.
- 1076 92. Balistreri CR, Monastero R: Neuroinflammation and Neurodegenerative Diseases:
- 1077 How Much Do We Still Not Know? Brain Sci 2023, 14.
- 107893.Zhang W, Xiao D, Mao Q, Xia H: Role of neuroinflammation in neurodegeneration
- 1079 **development.** *Signal Transduction and Targeted Therapy* 2023, **8:**267.
- 1080 94. Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV: Neurovascular dysfunction and
- 1081 **neurodegeneration in dementia and Alzheimer's disease.** *Biochim Biophys Acta*
- 1082 2016, **1862**:887-900.
- Müller N: The Role of Intercellular Adhesion Molecule-1 in the Pathogenesis of
 Psychiatric Disorders. Front Pharmacol 2019, 10:1251.
- 1085 96. Otgongerel D, Lee H-J, Jo SA: Induction of ICAM1 in Brain Vessels is Implicated in
- an Early AD Pathogenesis by Modulating Neprilysin. NeuroMolecular Medicine 2023,
 25:193-204.
- 1088 97. Bui TM, Wiesolek HL, Sumagin R: **ICAM-1: A master regulator of cellular responses**
- in inflammation, injury resolution, and tumorigenesis. *Journal of Leukocyte Biology*2020, **108**:787-799.
- 1091 98. Lawson C, Wolf S: ICAM-1 signaling in endothelial cells. *Pharmacol Rep* 2009, 61:221092 32.
- 1093 99. Lange C, Storkebaum E, de Almodóvar CR, Dewerchin M, Carmeliet P: Vascular
- endothelial growth factor: a neurovascular target in neurological diseases. Nature
 Reviews Neurology 2016, **12**:439-454.
- 1096 100. Yang H-S, Yau W-YW, Carlyle BC, Trombetta BA, Zhang C, Shirzadi Z, Schultz AP,
- 1097 Pruzin JJ, Fitzpatrick CD, Kirn DR, et al: Plasma VEGFA and PGF impact longitudinal
- 1098 tau and cognition in preclinical Alzheimer's disease. Brain 2024.

1099	101.	Bitto A, Lerner CA, Nacarelli T, Crowe E, Torres C, Sell C: p62/SQSTM1 at the interface
1100		of aging, autophagy, and disease. AGE 2014, 36:1123-1137.
	400	

- 1101 102. Rubino E, Rainero I, Chiò A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G,
- 1102 Calvo A, Gentile S, et al: **SQSTM1** mutations in frontotemporal lobar degeneration
- and amyotrophic lateral sclerosis. *Neurology* 2012, **79:**1556-1562.
- 1104 103. Muto V, Flex E, Kupchinsky Z, Primiano G, Galehdari H, Dehghani M, Cecchetti S,
- 1105 Carpentieri G, Rizza T, Mazaheri N, et al: Biallelic SQSTM1 mutations in early-onset,
- 1106 variably progressive neurodegeneration. *Neurology* 2018, **91:**e319-e330.
- 1107 104. Weston LL, Jiang S, Chisholm D, Jantzie LL, Bhaskar K: Interleukin-10 deficiency

exacerbates inflammation-induced tau pathology. *Journal of Neuroinflammation*2021, **18**:161.

- 1110 105. Hersh LB, Rodgers DW: Neprilysin and amyloid beta peptide degradation. *Curr* 1111 *Alzheimer Res* 2008, 5:225-231.
- 1112 106. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS: Neprilysin: An Enzyme
- 1113 Candidate to Slow the Progression of Alzheimer's Disease. The American Journal of
- 1114 *Pathology* 2008, **172**:1342-1354.
- 1115 107. Campos CR, Kemble AM, Niewoehner J, Freskgård P-O, Urich E: Brain Shuttle
- 1116 Neprilysin reduces central Amyloid-β levels. *PLOS ONE* 2020, **15**:e0229850.
- 1117 108. Kim YS, Joh TH: Matrix metalloproteinases, new insights into the understanding of
 1118 neurodegenerative disorders. *Biomol Ther (Seoul)* 2012, 20:133-143.
- 1119 109. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA,
- 1120 Lo EH, Montaner J: Increased Brain Expression of Matrix Metalloproteinase-9 After
- 1121 Ischemic and Hemorrhagic Human Stroke. Stroke 2006, **37:**1399-1406.
- 1122 110. Kwon HS, Koh S-H: Neuroinflammation in neurodegenerative disorders: the roles
- 1123 of microglia and astrocytes. *Translational Neurodegeneration* 2020, **9:**42.

- 1124 111. Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH: Neuroinflammation in
- 1125 Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics.
- 1126 Inflammation 2023, **46:1-17**.

Figure 1

A Detectability



Figure 2

Association between NULISAseq targets and $A\beta$ PET Α



В Significant NULISAseq targets

+

A+

I

ŧ

 \bot

Α-

ŧ

 \bot

‡ ‡

A٩

2-year

Α-

A





A٠

Baseline

Α.



18

12

Т

1

A٩

Baseline

L

Α.

Т

A+

2-year



тімрз (р < 0.0001)



ANXA5 (p = 0.0003)

Baseline 2-year

Figure 3



Figure 4



B Tau pathology-dependent longitudinal biomarker change



A NULISAseq targets exhibiting significant univariate association with N status



B Boxplot distributions by N status for selected NULISAseq targets



C Targets with N status-dependent change

